Chitomur

The blind randomized placebo-controlled study of the efficacy of bladder peptide bioregulator Chitomur for the treatment of older age groups of men with benign prostatic hyperplasia was conducted. The effect of the drug on the main urodynamic parameters, symptoms dynamic of the lower urinary tract function disturbances, prostate volume and the quality of life of men with benign prostatic hyperplasia in age from 62 to 83 years was evaluated. It was found that the course application of peptide bioregulator Chitomur in elderly and senile patients with benign prostatic hyperplasia significantly improves the basic parameters of urination. That was accompanied by improved quality of life of the patients. The achieved improvement of urodynamic parameters and quality of life does not reduce during the month following the end of treatment. No adverse effects of the drug were found during the study, which is important for elderly patients and distinguishes it from the conventional drugs used for the treatment of patients with benign prostatic hyperplasia.

A randomized blind study to assess effectiveness of peptide bioregulator Chitomur® in aged female patients with hyperactive bladder was conducted. The drug influence on urodynamic parameters and life quality of women with hyperactive bladder of the age of 48-80 years was researched. It was stated that Chitomur® administration cause not only to the decrease of imperative feelings of urination and episodes of urgent incontinention but significant improvement of bladder condition. As per patient self-assessment decrease of anxiety caused by urination disturbance symptoms becomes evident 1,5 times faster than the positive dynamics of these symptoms itself which means the treatment has improved the quality of life of these women. Drug's side effects were not detected during the study. That is significantly distinguishing the drug from commonly used medications used for the hyperactive bladder treatment.